Related Experiment Video

Updated: Jul 26, 2026

A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations
09:34

A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations

Published on: October 25, 2018

7.1K

TRIPODD Enables Single-Cell Quantification of Therapeutic Efficacy

Nathan P McMahon, Allison Solanki, Antonio R Montaño

  • 1Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois 60616, United States.

Molecular Pharmaceutics
|February 17, 2026
PubMed

Insights

We developed a novel imaging platform, TRIPODD, to analyze single-cell drug response and resistance in tumors. This technology quantifies drug distribution and therapeutic effects, aiding personalized cancer therapy development.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomedical Imaging

Background:

  • Targeted therapies like tyrosine kinase inhibitors (TKIs) improve cancer survival but often face transient responses due to tumor resistance.
  • Existing methods lack spatial resolution for quantitative analysis of drug delivery and response mechanisms.
  • Personalized cancer therapy requires understanding drug action and resistance at a single-cell level within the tumor microenvironment.

Purpose of the Study:

  • To evaluate the utility of the Therapeutic Response Imaging through Proteomic and Optical Drug Distribution (TRIPODD) platform for assessing single-cell response to epidermal growth factor receptor (EGFR) TKI therapy.
  • To demonstrate TRIPODD's capability in quantifying drug delivery and therapeutic response within the spatial context of a tumor.
  • To identify single-cell signatures of therapeutic response and resistance to EGFR-TKI treatment.

Main Methods:

  • Application of the quantitative fluorescence imaging platform, TRIPODD, to EGFR-TKI-sensitive non-small cell lung cancer (NSCLC) xenografts.
  • Quantification of erlotinib accumulation and engagement at the single-cell level within the tumor.
  • Analysis of spatial drug distribution and its correlation with therapeutic response and resistance.

Main Results:

  • TRIPODD successfully quantified the therapeutic response of NSCLC xenografts to erlotinib.
  • Unique single-cell signatures of therapeutic response were identified, linked to erlotinib accumulation and engagement.
  • The study demonstrated the platform's ability to evaluate treatment response and resistance in heterogeneous tumors at the single-cell level.

Conclusions:

  • The TRIPODD platform provides a quantitative, spatially resolved method for evaluating single-cell drug response and resistance.
  • TRIPODD enables a mechanistic understanding of drug delivery and therapeutic effects, crucial for personalized cancer therapy.
  • This technology holds promise for advancing the development and application of targeted cancer therapies by revealing treatment dynamics within heterogeneous tumors.
Keywords:
cancer heterogeneitycyclic immunofluorescencedrug target availabilityfluorescence imagingintracellular paired agent imaging

More Related Videos

Using High Content Imaging to Quantify Target Engagement in Adherent Cells07:23

Using High Content Imaging to Quantify Target Engagement in Adherent Cells

Published on: November 29, 2018

9.1K
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

2.0K

Related Concept Videos

Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma —...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...